Anti-CD30 Antibody Drug Conjugate Dosing for Neuropathy and Neutropenia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for mature T-cell lymphomas, particularly those expressing CD30, face challenges in achieving high complete remission rates and suffer from significant adverse effects such as peripheral neuropathy and neutropenia when using anti-CD30 antibody drug conjugates like brentuximab vedotin in combination with chemotherapy regimens like CHP (cyclophosphamide, doxorubicin, and prednisone).
Innovation Solution
Adjusting the dose and timing of anti-CD30 antibody drug conjugates and co-administering them with granulopoiesis stimulating factors like GCSF to reduce adverse effects, specifically targeting Grade 2 or greater peripheral neuropathy and neutropenia, while maintaining therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-CD30 antibody drug conjugate is administered at standard dose in combination with CHP chemotherapy, then therapeutic efficacy is improved, but peripheral neuropathy and neutropenia severity increases
Solution Approach 1:
The patent applies parameter changes by adjusting the dosage of anti-CD30 antibody drug conjugate based on neutropenia risk factors and administering granulopoiesis stimulating factors to modify the hematologic parameters, thereby reducing neutropenia severity while preserving therapeutic efficacy
Solution Approach 2:
The patent uses granulopoiesis stimulating factors as intermediary substances that mediate between the chemotherapy treatment and the bone marrow function, protecting against neutropenia by stimulating granulocyte production without interfering with the anti-tumor activity of the anti-CD30 antibody drug conjugate
2Object-affected harmful factors
If anti-CD30 antibody drug conjugate dose is reduced to minimize neuropathy, then adverse effects are decreased, but therapeutic efficacy may be compromised
Solution Approach 1:
The patent applies partial action by administering the anti-CD30 antibody drug conjugate at reduced doses only to patients who have lower risk of neuropathy, while providing full-dose therapy to those at lower risk, thereby optimizing the balance between efficacy and safety for different patient populations
Solution Approach 2:
The patent uses preliminary action by identifying neuropathy risk factors before treatment initiation and pre-stratifying patients into different dosing groups, allowing proactive adjustment of therapy intensity before adverse effects can develop
3Productivity
If chemotherapy regimen is intensified to improve complete remission rates, then response rates increase, but neutropenia incidence increases
Solution Approach 1:
The patent employs granulopoiesis stimulating factors as intermediary agents that protect bone marrow function during intensified chemotherapy, allowing higher doses of anti-CD30 antibody drug conjugate and CHP chemotherapy to be administered while maintaining neutrophil counts within safe ranges
Solution Approach 2:
The patent applies parameter changes by dynamically adjusting the dosage and timing of granulopoiesis stimulating factors based on neutrophil count monitoring, allowing flexible modification of treatment intensity to maximize remission rates while staying within safety parameters for neutropenia
Data Source
AI summary
The present disclosure, relates, in general to methods for improving adverse events in subjects having a mature T cell lymphoma and who are receiving treatment with an anti-CD30 antibody drug conjugate in combination with accompanying chemotherapy. Adverse events include peripheral neuropathy and neutropenia.